Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ)

Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
230. 93
+4.81
+2.1272%
$
14.91B Market Cap
17.91 P/E Ratio
- Div Yield
879,443 Volume
18.96 Eps
$ 226.12
Previous Close
Add Transaction
Day Range
224.99 231.49
Year Range
105 243.32
Want to track JAZZ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.

Zacks | 1 year ago
JAZZ vs. ARGX: Which Stock Is the Better Value Option?

JAZZ vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?

Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?

Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks | 1 year ago
JAZZ or ARGX: Which Is the Better Value Stock Right Now?

JAZZ or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 1 year ago
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?

Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 year ago
JAZZ or ILMN: Which Is the Better Value Stock Right Now?

JAZZ or ILMN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

Zacks | 1 year ago
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,

3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,

These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.

Zacks | 1 year ago
Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy?

Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy?

Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 1 year ago
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 1 year ago
Loading...
Load More